blood-based biomarkers as surrogates of amyloid burden in preclinical alzheimer's disease
Published 1 year ago • 63 plays • Length 6:37Download video MP4
Download video MP3
Similar videos
-
0:56
blood-based biomarkers for treatment monitoring in alzheimer’s disease
-
1:40
blood-based biomarkers for alzheimer’s disease screening
-
1:28
impact of blood-based biomarkers on alzheimer’s disease treatments
-
3:19
prognostic blood biomarkers in the pre-clinical stages of alzheimer’s disease
-
5:25
drop-ad: detecting alzheimer’s disease biomarkers in a single blood spot
-
3:41
amyloid-pet in the age of blood-based biomarkers
-
6:32
blood biomarkers in alzheimer’s disease: appropriate use recommendations
-
2:55
research priorities to achieve widespread use of blood-based biomarkers in alzheimer’s disease
-
3:42
biomarker blood tests as diagnostic tool for alzheimer's disease
-
2:48
biomarkers for alzheimer’s disease in a preclinical setting
-
2:50
the future of alzheimer’s disease diagnosis: blood biomarkers and amyloid-pet
-
1:02
blood biomarkers for the diagnosis of alzheimer's disease
-
2:31
diagnosing alzheimer’s disease using blood-based biomarkers
-
5:05
comparing the performance of blood-based amyloid and tau assays
-
5:19
exploring blood based biomarkers for alzheimer's disease - prof zetterberg
-
2:07
validating blood-based biomarker assays for use in alzheimer's disease clinical care
-
2:49
blood-based biomarkers for ad diagnosis
-
3:09
how are blood-based biomarkers currently used in alzheimer’s disease?
-
1:12
beyond aβ and p-tau: novel biomarkers under investigation for alzheimer’s disease